Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

被引：0
|
作者：
Jun Guo
Jie Jin
Mototsugu Oya
Hirotsugu Uemura
Shunji Takahashi
Katsunori Tatsugami
Sun Young Rha
Jae-Lyun Lee
Jinsoo Chung
Ho Yeong Lim
Hsi Chin Wu
Yen Hwa Chang
Arun Azad
Ian D. Davis
Marlene J. Carrasco-Alfonso
Bhupinder Nanua
Jackie Han
Qasim Ahmad
Robert Motzer
机构：
[1] Peking University Cancer Hospital and Institute,Department Urology and Melanoma
[2] Peking University First Hospital,Department of Urology
[3] Keio University School of Medicine,Department of Urology
[4] Kindai University Faculty of Medicine,Department of Urology
[5] Cancer Institute Hospital,Department of Medical Oncology
[6] Japanese Foundation for Cancer Research,Department of Urology, Graduate School of Medical Sciences
[7] Kyushu University,Department of Oncology and Internal Medicine, Asan Medical Center
[8] Yonsei Cancer Center,Department of Urology
[9] Yonsei University College of Medicine,Division of Hematology
[10] University of Ulsan College of Medicine,Oncology
[11] Center for Prostate Cancer,Department of Urology
[12] National Cancer Center,Division of Urology, Department of Surgery
[13] Samsung Medical Center,Department of Medicine
[14] Sungkyunkwan University,Department of Medicine
[15] China Medical University Hospital,undefined
[16] Taipei Veterans General Hospital,undefined
[17] Monash University,undefined
[18] Monash University,undefined
[19] Eastern Health Clinical School,undefined
[20] Novartis Pharmaceuticals Corporation,undefined
[21] Novartis Pharmaceuticals Corporation,undefined
[22] Genitourinary Oncology Service,undefined
[23] Memorial Sloan-Kettering Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Renal cell carcinoma; Pazopanib; Sunitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naive metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.
    George, Saby
    Herbst, Laurie
    Sikorski, Marcus
    Diraddo, Ann Marie
    Azabdaftari, Gissou
    Roche, Charles
    Kauffman, Eric
    Li, Qiang
    Schwaab, Thomas
    Levine, Ellis Glenn
    Pili, Roberto
    Chatta, Gurkamal S.
    Appleman, Leonard Joseph
    Groman, Adrienne
    Parikh, Rahul Atul
    Hutson, Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [32] Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study)
    Xu, Chun-Fang
    Johnson, Toby
    Choueiri, Toni K.
    Deen, Keith C.
    Xue, Zhengyu
    Spraggs, Colin F.
    Bartlett-Pandite, Arundathy N.
    Carpenter, Christopher
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] COST EFFECTIVENESS OF SUNITINIB VERSUS PAZOPANIB AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN CHILE
    Vargas, C.
    Espinoza, M. A.
    Giglio, A.
    VALUE IN HEALTH, 2016, 19 (07) : A736 - A736
  • [34] Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
    Tan, Daniel S. W.
    Geater, Sarayut
    Yu, Chong-Jen
    Tsai, Chun -Ming
    Hsia, Te-Chun
    Chen, Jun
    Lin, Meng-Chih
    Lu, You
    Sriuranpong, Virote
    Yang, Cheng-Ta
    Sen, Paramita
    Branle, Fabrice
    Shi, Michael
    Wu, Yi-Long
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (03):
  • [35] Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC)
    Rini, Brian I.
    Powles, Thomas
    Chen, Mei
    Puhlmann, Markus
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Safety and efficacy of pazopanib in heavily pretreated and treatment-naive patients with metastatic renal cell carcinoma (mRCC): A single center experience of the Medical University of Vienna, Austria.
    Schmidinger, Manuela
    Bojic, Marija
    Vogl, Ursula Maria
    Klingler, Christoph
    Kramer, Gero
    Zielinski, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] COST-UTILITY ANALYSIS OF PAZOPANIB VERSUS SUNITINIB AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN SPAIN
    Espinosa, J.
    Gonzalez-Larriba, J. L.
    Maroto, P.
    Mendez-Vidal, M. J.
    Diaz-Cerezo, S.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A633
  • [38] Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
    Liu, Xiaoyan
    Fiocco, Marta
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    ACTA ONCOLOGICA, 2017, 56 (04) : 582 - 589
  • [39] Phase II trial of tepotinib vs sorafenib for treatment-naive advanced hepatocellular carcinoma (HCC) in Asian patients
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
    Choueiri, Toni K.
    Figueroa, David J.
    Fay, Andre P.
    Signoretti, Sabina
    Liu, Yuan
    Gagnon, Robert
    Deen, Keith
    Carpenter, Christopher
    Benson, Peter
    Ho, Thai H.
    Pandite, Lini
    de Souza, Paul
    Powles, Thomas
    Motzer, Robert J.
    CLINICAL CANCER RESEARCH, 2015, 21 (05) : 1071 - 1077
12345